IntoCell was established with a bold vision of commercializing innovative ADC platform technologies based on creative ideas and technical excellence, breaking away from traditional small molecule-based drug discovery and development.
IntoCell’s leadership team already has management experience in co-founding a venture company that subsequently listed on the KOSDAQ stock exchange. By combining extensive experience in successfully developing ADC technologies with a broad industry network, we are confident that our vision will come to be realized.
IntoCell has already succeeded in proving the concept behind its original ideas through diligent and practical research and development. It is now focusing on finding partners for its technology platform and the in-house development of therapeutic candidates in the anti-cancer area.
Tae-Kyo Park, CEO of IntoCell